Search Results 531-540 of 18016 for Alopecia

1. Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

   All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse ...

2. Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) - Mayo Clinic

   Complete resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the subject received major surgery or ...

3. A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;; Women of child bearing potential (WCBP), defined ...

4. Hidradenitis suppurativa - Diagnosis and treatment - Mayo Clinic

   Uso de la espironolactona en dermatología: Acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas Dermosifiliogr. 2020; doi: 10.1016/j.ad ...

5. A Study to Evaluate Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAFV600E Mutation - Mayo Clinic

   EXCEPTIONS: Stable chronic conditions (≤ grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related ...

6. Sirolimus (oral route) - Side effects & dosage - Mayo Clinic

   Sirolimus is used together with other medicines to prevent the body from rejecting a transplanted kidney. It belongs to a group of medicines known as ...

7. A Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination with Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14) - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities, such as alopecia). Age 18 or ...

8. A Study of IPI-926 for Patients with Myelofibrosis - Mayo Clinic

   ... alopecia; Females. Be of non-child bearing potential; If of child-bearing potential defined as a sexually mature woman who. Has not undergone surgical ...

9. Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab - Mayo Clinic

   Patients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia).

10. Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma - Mayo Clinic

    Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for ...